Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | TK2 | O00142 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22992579 | 0.90 | TK1 (0.48) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL8176500 | 0.88 | LMNA (0.46) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL8176498 | 0.88 | LMNA (0.46) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL27054419 | 0.85 | TK1 (0.48) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL24420515 | 0.85 | TK1 (0.48) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL24420755 | 0.85 | TK1 (0.48) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL16348682 | 0.85 | TK1 (0.48) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL4810094 | 0.82 | TK1 (0.51) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL4810101 | 0.82 | TK1 (0.51) | TK1LMNASMN1; SMN2ADRB1DNMT1 | |
| SCHEMBL25295079 | 0.78 | TK1 (0.45) | TK1LMNASMN1; SMN2ADRB1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104754-A1 | CELL CULTURE MEDIUM | GENETIX LIMITED | 2011-05-05 | — | — | US | disclosed |
| EP-1818392-B1 | Cell culture medium | GENETIX LTD (GB) | 2010-08-25 | — | — | EP | disclosed |
| EP-0948256-A4 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | UNIV WASHINGTON (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070212778-A1 | Cell culture medium | GENETIX LIMITED | 2007-09-13 | — | — | US | disclosed |
| EP-1818392-A1 | Cell culture medium | Genetix Limited (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-08-25 | — | — | US | disclosed |
| US-6887707-B2 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-05-03 | — | — | US | disclosed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | disclosed |
| US-6063628-A | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2000-05-16 | — | — | US | disclosed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | TK1 565/4885LMNA 3576/4885SMN1; SMN2 2456/4885 |
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | TK1 565/4885LMNA 3576/4885SMN1; SMN2 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.